Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis

This study is open to adults aged 18 or older who have psoriatic arthritis. It's specifically for people who have already taken part in one of the previous tildrakizumab studies (INSPIRE 1 or INSPIRE 2).

To join, you must have finished the previous study without having to stop treatment early for any reason. You also need to be able to understand what's involved in the study and agree to follow all the study rules and visit schedules.

There are some reasons why you wouldn't be able to join. For example, if you are pregnant, breastfeeding, or planning to become pregnant or breastfeed soon. Women who could become pregnant must agree to use effective birth control throughout the study and for a period afterwards. Also, if you've already been in this specific long-term study, you can't join again, or if the study doctor thinks it wouldn't be safe for you.

If you decide to take part, you'll be given the study medicine, tildrakizumab, as an injection under your skin. This is an 'open-label' study, which means both you and the doctors will know you are receiving the active medicine. You will have regular visits to the study clinic where the team will monitor your health, check your psoriatic arthritis, and record how you're feeling and any side effects. These visits will involve various assessments, which might include blood tests, physical examinations, and questionnaires about your symptoms and quality of life. The exact number and frequency of visits, as well as the total duration of your participation, will be clearly explained by the study team. You will be expected to attend all scheduled appointments and follow the study instructions carefully.